What is the most accurate statement regarding roflumilast (Daliresp) in COPD patients?

The most accurate statement regarding roflumilast (Daliresp) in COPD patients is that it can reduce the risk of exacerbations in severe COPD. Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor, which works by reducing inflammation in the lungs. This anti-inflammatory effect is particularly beneficial for patients with severe COPD, as it helps to stabilize their condition and decrease the frequency of exacerbations—sudden worsening of symptoms that can lead to hospitalizations and decreased quality of life.

Unlike traditional bronchodilators that are designed specifically to open up the airways and relieve symptoms, roflumilast is not a bronchodilator itself and does not provide immediate relief from acute bronchospasm. This distinguishes it from medications that are used for acute symptom management in COPD. Additionally, despite roflumilast being used in some treatment regimens, it can be safely used in conjunction with Long-Acting Beta Agonists (LABA) for enhanced management of COPD symptoms, contrary to the suggestion that it should not be combined with LABA therapy. Thus, option C reflects the medication's role in long-term disease management and its impact on preventing exacerbations, making it the most